AbbVie, Enanta Pharma rise after US FDA approves pediatric use of hepatitis C drug

Enanta Pharmaceuticals

11/06/2025 19:07

** Shares of drugmaker AbbVie ABBV.N up 1.5% at $192.40 and biotech company Enanta Pharma ENTA.O up 7.1% to $8.12

** AbbVie says the U.S. FDA approves expanded use of its drug, Mavyret, for the treatment of adults and pediatric patients three years and older with hepatitis C virus (HCV) infection

** Mavyret was first approved by the FDA in August 2017 to treat hepatitis C virus (HCV) infection in adults

** Hepatitis C is a viral infection that causes liver swelling that can lead to serious liver damage

** Mavyret was developed through a collaboration between AbbVie and Enanta Pharma

** Including session's moves, ABBV up 8.3% and ENTA up 33.2% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))